GSK 达成一笔 22 亿美元的收购

丁香园 Insight 数据库
Jan 20

1 月 20 日,GSK 宣布已达成最终协议,收购 RAPT Therapeutics。RAPT 致力于为炎症和免疫疾病患者开发创新疗法。此次收购包括 Ozureprubart,一种长效抗免疫球蛋白 E(IgE)单克隆抗体,目前正处于 IIb 期临床开发阶段,用于预防食物过敏。截图来源:企业官网根据协议条款,GSK 将在交易完成时向 RAPT Therapeutics 股东支付每股 58.00 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10